{'fraction_non_alphanumeric': 0.03213166144200627, 'fraction_numerical': 0.014890282131661442, 'mean_word_length': 5.5487179487179485, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Metabolite Predictors of HOMA in At‐Risk for Mobility Disability Elderly Subjects

The aim of this study was to evaluate the relationship between fasting serum levels of analytes and metabolites with the homeostasis model assessment of insulin resistance (HOMA), in at‐risk for mobility disability elderly subjects (avg. SPPB, 8.5). 73 participants (30 males, 43 females; avg. age, 78y) participated in the study. Serum analytes and metabolites were measured with use of the traditional chemistry screen and untargeted mass spectrometry‐based metabolomics, respectively. HOMA was calculated based on measurements of serum glucose and insulin. Sex and age‐adjusted linear regression was used to identify covariates significantly associated with HOMA (p≤0.05, q≤0.30), followed by stepwise multivariable linear regression on all significant covariates. BMI, eleven metabolites and two analytes were found to contain significant associations with HOMA. Sex and age‐adjusted stepwise regression identified the combination of BMI, four metabolites and one analyte to explain 51.6% of the variability inherent in HOMA. The evidence presented in the current study is the first attempt to identify baseline serum predictors of HOMA in at‐risk for mobility disability elderly subjects.